ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Parkinson's Disease Therapeutics Market The Parkinson's therapeutics market will grow from USD 5.92 Bn in 2024 to USD 12.83 Bn by 2033 at 8 ...

Here are a couple of ASX 200 shares that analysts are tipping to rise strongly from current levels. Here's what you need to ...

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into broader ...

AudioCodes AUDC is estimated to report quarterly earnings at $0.14 per share on revenue of $60.05 million. • AstraZeneca AZN is expected to report quarterly earnings at $1.1 ...

As the U.S. stock market navigates a landscape of fluctuating indices and economic indicators, investors are closely monitoring the Federal Reserve's interest rate decisions and major tech earnings ...